Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Pharmacological strategies to treat attacks of episodic migraine in adults

Publikation: Bidrag til tidsskriftReviewForskningpeer review

  1. Pharmacotherapeutic considerations in women with multiple sclerosis

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

  2. Clinical pharmacology of imeglimin for the treatment of type 2 diabetes

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

  3. The efficacy and safety of exenatide once weekly in patients with type 2 diabetes

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

  4. Non-insulin pharmacological therapies for treating type 1 diabetes

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  5. Exenatide: pharmacokinetics, clinical use, and future directions

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

  1. Erenumab prevents the occurrence of migraine attacks and not just migraine days: Post-hoc analyses of a phase III study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Can tendon reflexes be elicited by both stretch and vibration in man?

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Onset of action in placebo-controlled migraine attacks trials: A literature review and recommendation

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

  4. Pain freedom after 2 hours should be the primary outcome in controlled trials treating migraine attacks

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer

INTRODUCTION: Migraine patients prioritize early complete relief of headache and associated symptoms, sustained freedom of pain, and good tolerability. One major obstacle for the successful use of drug treatment of migraine attack is that the speed of action of triptans, 5-HT1B/1D receptor agonists, is delayed.

AREAS COVERED: In this review, the author discusses the following features of acute migraine drugs: pharmacology; pharmacokinetics, and absorption of drugs during migraine attacks. Next, dose-response curves for effect; and the delayed onset of action is reviewed. In the more clinical part of the review, the following items are discussed: overall clinical judgments; comparison of triptans; comparison of triptans with NSAIDs; early intervention with triptans; medication-overuse headache; comments on the effect of gepants; and the general principle of acute migraine therapy.

EXPERT OPINION: The delay in the onset of effect of acute migraine drugs is likely due to a complex antimigraine system involving more than one site of action. Investigations into the mechanisms of the delay should have a high priority, both in studies with animals, migraine models, and in migraine patients during attacks. Non-oral administration of antimigraine drugs resulting in early absorption of drugs should be developed as they possibly also can increase Emax.

OriginalsprogEngelsk
TidsskriftExpert Opinion on Pharmacotherapy
Vol/bind22
Udgave nummer3
Sider (fra-til)305-316
Antal sider12
ISSN1465-6566
DOI
StatusUdgivet - 2021

ID: 66965943